San Diego, CA, United States

Neurocrine Biosciences

www.neurocrine.com
San Diego, CA, United States

Neurocrine Biosciences is a biopharmaceutical company founded in 1992 and located in San Diego, California. The company tooks its name from the original focus on therapies for neurological and endocrine diseases and disorders.The company endured a significant setback on May 16, 2006 when the Food and Drug Administration denied approval for the 15-milligram dose of Indiplon, a medication to treat insomnia. Neurocrine had developed the drug and was seeking to market it with partner, Pfizer. Announcement of the setback led to a 62% drop in stock price. Subsequent disclosures related to attempts to overcome this major setback caused a further drop in the stock by 30% in November 2006.Lacking approval for Indiplon, the company laid off a 200-member sales force in July, 2006 and 100 employees across all areas of the company on August 7, 2006. It announced a further cut of half the remaining workforce in December 2007, and a fourth quarter loss of $128 million, including a $94 million write-off.But recently the company has recovered the long term hope for recovery. All started on the 25th of May, 2010 when the shares jumped nearly 25% after the company announced its drug to treat endometriosis had achieved its main and secondary goals in a study.The drug, called elagolix, reportedly showed statistically significant reductions in dysmenorrhea, or pelvic pain during menstruation as well as painful intercourse. And the shares of the company were up 69 cents to $3.40 on May the 25th trading, hitting a 52-week high of $4.23 early in the trading session.But since that the stock has climbed from $4.23 to $6.16 at 25 June 2010. And the expectatives for NBIX has raised about the elagolix trial success and of the sign for development deal with Boehringer. and Abbott Laboratories. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Neurocrine Biosciences | Date: 2016-10-28

Provided herein are salts of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester in amorphous and crystalline forms, and processes of preparation, and pharmaceutical compositions thereof. Also provided are methods of their use for treating, preventing, or ameliorating one or more symptoms of neurological disorders and diseases including hyperkinetic movement disorders or diseases.


Provided herein are processes for the preparation of (S)-(2R,3R,11bR-3-isobuty-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate), or a solvate, hydrate, or polymorph thereof.


Patent
Neurocrine Biosciences | Date: 2017-03-15

Methods for treating hyperkinetic diseases and disorders, such as tardive dyskinesia, are provided. In a certain embodiment, the potent VMAT2 inhibitor (+)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol ((+)-HTBZ) is used in the methods described herein for treating a subject in need thereof.


Patent
Neurocrine Biosciences | Date: 2015-05-06

Methods for treating hyperkinetic diseases and disorders, such as tardive dyskinesia, are provided. In a certain embodiment, the potent VMAT2 inhibitor (+)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol ((+)-HTBZ) is used in the methods described herein for treating a subject in need thereof.


Williams J.P.,Neurocrine Biosciences
Expert Opinion on Therapeutic Patents | Year: 2013

Introduction: Corticotropin-releasing factor (CRF) is a 41 amino acid peptide hypothalamic factor that plays a key role in the body's response to stress. The receptors for CRF (CRF1 and CRF2) are members of the class B G-protein coupled receptor family and several small molecule antagonists have been evaluated clinically in stress-related disorders. Areas covered: The present review covers the disclosures of non-peptide CRF1 antagonists in the patent literature since 2006. Expert opinion: Antagonists of the CRF1 receptor have failed to demonstrate clinical utility. All of the compounds evaluated are similar structures and are allosteric inhibitors of the CRF1 receptor. Further clinical evaluation of new compounds appears unlikely unless novel structures are identified that interact with the receptor distinct to the first-generation antagonists. © 2013 Informa UK, Ltd.


New methods of treating schizophrenia and schizoaffective disorder by administration of pharmaceutical compositions comprising an antipsychotic compound and a VMAT2 inhibitor to a subject in need thereof are provided.


GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R_(1a), R_(1b), R_(1c), R_(1d), R_(2), R_(2a), and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.


Patent
Neurocrine Biosciences | Date: 2016-01-29

Substituted 1,2,3-triazole compounds are disclosed which have utility in the treatment of a variety of neurological disorders. The compounds provided herein have the general structure: wherein R_(1), R_(2), R_(3 )and n are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound provided herein in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for treating neurological disorders in a subject in need thereof.


Compounds having a structure of formula (I), including stereoisomers and pharmaceutically acceptable salts and solvates thereof: wherein R_(1 )is as defined herein. Such compounds are inhibitors of the vesicular monoamine transporter 2 (VMAT2) and have utility for treating, for example, hyperkinetic disorders. Also disclosed are compositions containing these compounds in combination with a pharmaceutically acceptable carrier or diluent, as well as methods relating to the use in a subject in need thereof.


CRF_(1 )receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.

Loading Neurocrine Biosciences collaborators
Loading Neurocrine Biosciences collaborators